Nobias Therapeutics Appoints Patrick Dougherty as CEO to Lead Next Phase of Growth

Philadelphia, November 14, 2024 (PRNewswire) -- Nobias Therapeutics has named Patrick Dougherty as its Chief Executive Officer, marking a pivotal leadership transition as the company sharpens its focus on advancing its lead asset, NB-001. Dougherty brings over 20 years of life sciences experience, including leadership roles at GSK, WindMIL Therapeutics, and as the founder of Beech Street Advisors.

Read full article here.